We are live on ! Find out more
IMVT icon

Immunovant
IMVT

215 hedge funds and large institutions have $2.75B invested in Immunovant in 2026 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 93 increasing their positions, 40 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

619% more call options, than puts

Call options by funds: $61.3M | Put options by funds: $8.52M

133% more repeat investments, than reductions

Existing positions increased: 93 | Existing positions reduced: 40

92% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 24

10% more funds holding

Funds holding: 196 → 215 (+19)

1% less capital invested

Capital invested by funds: $2.76B → $2.75B (-$14.3M)

7.63% less ownership

Funds ownership: 61.96% → 54.34% (-7.6%)

13% less funds holding in top 10

Funds holding in top 10: 8 → 7 (-1)

Holders
215
Holders Change
+19
Holders Change %
+9.69%
% of All Funds
2.65%
Holding in Top 10
7
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-12.5%
% of All Funds
0.09%
New
46
Increased
93
Reduced
40
Closed
24
Calls
$61.3M
Puts
$8.52M
Net Calls
+$52.8M
Net Calls Change
+$26.3M

Top Buyers

1
TCM
TCG Crossover Management
California
+$72.4M
2
Jennison Associates
Jennison Associates
New York
+$64.6M
3
FCM
Farallon Capital Management
California
+$39.7M
4
State Street
State Street
Massachusetts
+$19.4M
5
Bank of America
Bank of America
North Carolina
+$15M

Top Sellers

1
AC
Armistice Capital
New York
-$56.5M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$50.8M
3
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$37.5M
4
Morgan Stanley
Morgan Stanley
New York
-$25.1M
5
SCM
Soleus Capital Management
Connecticut
-$22.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$421M -$1.11M -42,866 -0.3%
DTC
2
Deep Track Capital
Connecticut
$286M – – –
BlackRock
3
BlackRock
New York
$163M +$13.4M +516,281 +9%
BBA
4
Baker Bros. Advisors
New York
$136M – – –
State Street
5
State Street
Massachusetts
$113M +$19.4M +751,003 +20%
TCM
6
TCG Crossover Management
California
$111M +$72.4M +2,797,055 +168%
Morgan Stanley
7
Morgan Stanley
New York
$96.3M -$25.1M -969,508 -20%
VPM
8
Vanguard Portfolio Management
Pennsylvania
$92M +$95.9M +3,704,905 New
VCM
9
Vanguard Capital Management
Pennsylvania
$89.9M +$93.7M +3,620,050 New
T. Rowe Price Investment Management
10
T. Rowe Price Investment Management
Maryland
$89.7M -$37.5M -1,447,539 -29%
AC
11
Armistice Capital
New York
$88.6M -$56.5M -2,182,239 -38%
TSC
12
Two Seas Capital
New York
$79.5M +$8.67M +335,000 +12%
Jennison Associates
13
Jennison Associates
New York
$79.4M +$64.6M +2,496,241 +356%
RI
14
RTW Investments
New York
$78.9M -$26 -1 -0%
ACM
15
ADAR1 Capital Management
Texas
$66.5M +$5.13M +198,042 +8%
AGM
16
Alpine Global Management
New York
$65.5M +$265K +10,233 +0.4%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$52M +$6.07M +234,570 +13%
WP
18
Woodline Partners
California
$49.1M – – –
Goldman Sachs
19
Goldman Sachs
New York
$44.3M +$12.7M +489,099 +38%
PA
20
Perceptive Advisors
New York
$39.7M -$10.3M -397,507 -20%
FCM
21
Farallon Capital Management
California
$38.4M +$39.7M +1,534,000 +12,783%
Aberdeen Group
22
Aberdeen Group
United Kingdom
$28.8M -$605K -23,360 -2%
LGM
23
Logos Global Management
California
$26.7M -$7.77M -300,000 -22%
Bank of America
24
Bank of America
North Carolina
$22.2M +$15M +580,197 +185%
SC
25
Stempoint Capital
New York
$18.5M +$2.63M +101,535 +16%
1
2 3 4 5

IMVT Hedge Fund Activity: Q1 2026 in Review

215 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q1 2026, worth a combined $2.75B — down 0.52% from $2.76B a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new IMVT positions and 24 closed out — a net gain of 22 holders — while 93 added to existing stakes and 40 trimmed.

The largest buyer was TCG Crossover Management, adding an estimated $72.4M. The largest seller was Armistice Capital, cutting an estimated $56.5M.

  • 215 institutional investors held Immunovant (IMVT) as of Q1 2026, up from 196 in Q4 2025.
  • Funds reported $2.75B of Immunovant stock for Q1 2026, down 0.52% quarter-over-quarter.
  • 46 funds opened new Immunovant positions in Q1 2026 and 24 closed out, a net change of +22 holders.
  • The largest Immunovant buyer in Q1 2026 was TCG Crossover Management, an estimated $72.4M added.
  • The largest Immunovant seller in Q1 2026 was Armistice Capital, an estimated $56.5M sold.

Based on aggregated 13F filings for Q1 2026.